Tenecteplase or Alteplase Better in Patients with Acute Ischemic Stroke Due to Large Vessel Occlusion: A Single Center Observational Study

特奈特普酶 医学 溶栓 纤溶剂 优势比 组织纤溶酶原激活剂 冲程(发动机) 单中心 瑞替普酶 内科学 心脏病学 外科 麻醉 心肌梗塞 机械工程 工程类
作者
Agnete Teivane,Kristaps Jurjāns,Jānis Vētra,Jekaterina Grigorjeva,Karlis Kupcs,Rytis Masiliūnas,Evija Miglāne
出处
期刊:Medicina-lithuania [Multidisciplinary Digital Publishing Institute]
卷期号:58 (9): 1169-1169
标识
DOI:10.3390/medicina58091169
摘要

Background and Objectives: The study aimed to investigate the efficacy of intravenous thrombolysis with Tenecteplase before thrombectomy for acute ischemic stroke (AIS) patients compared with previous results using Alteplase. Previous trials for Tenecteplase have indicated an increased incidence of vascular reperfusion. In April 2021, we started to primarily give Tenecteplase to patients eligible to undergo thrombectomy. Materials and Methods: In this retrospective observational single-center non-randomized study, we analyzed directly admitted patients with AIS who had occlusion of the internal carotid, middle cerebral, or basilar artery and who underwent thrombectomy, as well as the recanalization rate for these patients at the first angiographic assessment (mTICI score 2b-3), and complications. Results: We included 184 patients (demographic characteristics did not differ between Tenecteplase and Alteplase groups (mean age 68.4 vs. 73.0 years; female sex 53.3% vs. 51.1%, NIHSS 14 (IQR 4-26) vs. 15 (2-31). Forty-five patients received Tenecteplase and 139 Alteplase before endovascular treatment (EVT). Pre-EVT (endovascular treatment) recanalization was more likely to occur with Tenecteplase rather than Alteplase (22.2% vs. 8.6%, p = 0.02). Successful reperfusion (mTICI 2b-3) after EVT was achieved in 155 patients (42 (93.4%) vs. 113 (81.3), p = 0.07). Hemorrhagic imbibition occurred in 15 (33.3%) Tenecteplase-treated patients compared with 39 (28.1%) Alteplase-treated patients (p = 0.5). Patients treated with Tenecteplase had higher odds of excellent functional outcome than Alteplase-treated patients (Tenecteplase 48.6% vs. Alteplase 26.1%; OR 0.37 (95% CI 0.17-0.81), p = 0.01). Conclusions: Tenecteplase (25 mg/kg) could have superior clinical efficacy over Alteplase for AIS patients with large-vessel occlusion (LVO), administered before EVT. The improvement in reperfusion rate and the better excellent functional outcome could come without an increased safety concern.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
文献完成签到,获得积分20
2秒前
orixero应助务实青亦采纳,获得10
2秒前
h4ra1n完成签到,获得积分10
2秒前
大模型应助彩色的沛白采纳,获得30
2秒前
2秒前
梓歆发布了新的文献求助10
3秒前
wxy完成签到,获得积分10
3秒前
wanci应助哈哈哈采纳,获得10
4秒前
不吃辣活不了完成签到,获得积分10
4秒前
JMao完成签到,获得积分10
4秒前
4秒前
曾经的苑博完成签到,获得积分10
4秒前
佰斯特威应助sherry221采纳,获得10
4秒前
5秒前
Alisa发布了新的文献求助10
5秒前
Owen应助宇与鱼采纳,获得10
5秒前
独特斩完成签到,获得积分10
5秒前
6秒前
6秒前
yulongmin发布了新的文献求助10
6秒前
畅快蓝血完成签到,获得积分10
7秒前
7秒前
赵赵赵发布了新的文献求助10
7秒前
7秒前
小白应助qiqishao采纳,获得10
7秒前
金容完成签到,获得积分10
8秒前
逃跑的炸鸡完成签到 ,获得积分10
8秒前
9秒前
Zll完成签到,获得积分10
9秒前
A爷有特点完成签到 ,获得积分10
10秒前
10秒前
林林发布了新的文献求助10
11秒前
深情安青应助meimei采纳,获得30
11秒前
angelinazh发布了新的文献求助30
11秒前
甜美三娘发布了新的文献求助10
11秒前
独特的莫言完成签到,获得积分10
11秒前
12秒前
小叮当发布了新的文献求助30
13秒前
科研通AI5应助反差小猴采纳,获得10
13秒前
JohanXu完成签到,获得积分10
14秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
Production Logging: Theoretical and Interpretive Elements 3000
CRC Handbook of Chemistry and Physics 104th edition 1000
Density Functional Theory: A Practical Introduction, 2nd Edition 840
J'AI COMBATTU POUR MAO // ANNA WANG 660
Izeltabart tapatansine - AdisInsight 600
Gay and Lesbian Asia 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3755562
求助须知:如何正确求助?哪些是违规求助? 3298696
关于积分的说明 10106720
捐赠科研通 3013351
什么是DOI,文献DOI怎么找? 1655100
邀请新用户注册赠送积分活动 789453
科研通“疑难数据库(出版商)”最低求助积分说明 753286